Krystal Biotech, Inc. (KRYS) is a pioneering gene therapy company that is pushing the boundaries of scientific discovery and developing innovative treatments for individuals struggling with rare and debilitating illnesses. The company is publicly traded on the Nasdaq stock exchange under the ticker symbol "KRYS."
Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech is committed to harnessing the power of human biology to deliver transformative medicine to patients in need. The company's proprietary gene therapy platform, known as STAR-D, leverages skin-targeted in vivo treatments and novel vector design to deliver therapeutic genes to affected tissues.
One of Krystal Biotech's lead investigational products is "brynk", a vector-engineered, topically-delivered gene therapy designed to form functional COL7A protein for the treatment of dystrophic epidermolysis bullosa, a severe, life-threatening skin disorder.
Another investigational product is "xelefy", which is being developed for the treatment of patients with the rare genetic disease, congenital ichthyosis. Both "brynk" and "xelefy" are currently undergoing clinical trials, and the promising preliminary results hint at their potential to provide effective treatments for patients stuck with disorders that currently lack any form of cure.
Beyond these products, Krystal Biotech also has a pipeline of other gene therapies addressing disorders for which there are currently insufficient treatment options. These therapies underscore the company’s commitment to delivering cutting-edge biomedical solutions by pushing the boundaries of modern medicine.
As of today, Krystal Biotech is led by a team of seasoned executives and scientists with a deep understanding of the genetic disease field. Despite being a relatively young company, Krystal has made significant progress in its understanding and application of gene therapy in a few short years, a testament to its commitment and ability to drive cutting-edge therapeutic development.
With a strong balance sheet and funding from public and private investors, including leading healthcare and biotech funds, Krystal Biotech is well-capitalized to proceed on its path of innovation.
While the journey to broaden the scope of gene therapy is challenging, Krystal Biotech is committed to the mission of delivering novel treatments to patients with rare genetic diseases. It represents a beacon of hope for those who are grappling with these devastating illnesses, often with few or no treatment options. Through its passionate pursuit of innovation, Krystal Biotech is truly showcasing what is possible when science and empathy come together to tackle some of the most challenging health issues of our time.